ImClone Systems Inc. (IMCL), Eli Lilly (LLY) to Benefit from the Strategic Combination, Bristol-Myers won't Boost Bid, Article Posted on BeaconEquity.com
In an effort to expand its presence in the oncology market, Eli Lilly recently made an offer to buy ImClone Systems in a $6.5 Billion transaction. Several days ago, Carl Icahn ImClone's chairman of the board, stated that a large pharma company has complet
(EMAILWIRE.COM, October 08, 2008 ) DALLAS, Texas - BeaconEquity.com announces the publication of “ImClone Systems Inc. (IMCL), Eli Lilly (LLY) to Benefit from the Strategic Combination, Bristol-Myers won't Boost Bid.” The article discusses Eli Lilly’s $6.5 billion offer to purchase ImClone and what it means to shareholders and Bristol-Myers.
Investors can view all of the investment articles for free by visiting: http://www.beaconequity.com/m - Click on News and Commentary
In the article the author writes:
"In an effort to expand its presence in the oncology market, Eli Lilly recently made an offer to buy ImClone Systems in a $6.5 Billion transaction. Several days ago, Carl Icahn ImClone's chairman of the board, stated that a large pharma company has completed due diligence and made a proposal not subject to financing or further due diligence, but requested that ImClone not divulge its name until negotiations are completed.”
In response to Eli Lilly’s offer, Bristol-Myers refused to raise its $62 per share bid for ImClone:
“Commenting on the Eli Lilly-Imclone deal, Bristol-Myers said it will not raise its $62 as share bid for ImClone. According to Bristol-Myers, which already holds a 16.6% stake in Imclone, raising the bid was not in the best interest of its shareholders.”
To read the entire article visit http://www.beaconequity.com/m – Click on News and Commentary
Join the fastest growing investor community at: http://www.stockhideout.com/
BeaconEquity.com’s Market News is one of the fastest growing small cap blogs in the investment community. Beacon is the authority on research in the small cap sector, and our analysts strive each day to find the stocks that are poised to be the biggest movers before the rest of the market is aware of them.
We encourage investors to subscribe to our FREE newsletter filled with daily trading ideas by visiting:
http://www.beaconequity.com/m
BeaconEquity.com is one of the industry’s largest small cap research providers. Beacon strives to provide a balanced view of many promising small cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the publicly available information available on them. For more information on Beacon Research, please visit: http://www.beaconequity.com/m
Source: BeaconEquity.com
Beacon Equity Research
Jeff Bishop, (469)-252-3505
press@beaconequity.com
Investors can view all of the investment articles for free by visiting: http://www.beaconequity.com/m - Click on News and Commentary
In the article the author writes:
"In an effort to expand its presence in the oncology market, Eli Lilly recently made an offer to buy ImClone Systems in a $6.5 Billion transaction. Several days ago, Carl Icahn ImClone's chairman of the board, stated that a large pharma company has completed due diligence and made a proposal not subject to financing or further due diligence, but requested that ImClone not divulge its name until negotiations are completed.”
In response to Eli Lilly’s offer, Bristol-Myers refused to raise its $62 per share bid for ImClone:
“Commenting on the Eli Lilly-Imclone deal, Bristol-Myers said it will not raise its $62 as share bid for ImClone. According to Bristol-Myers, which already holds a 16.6% stake in Imclone, raising the bid was not in the best interest of its shareholders.”
To read the entire article visit http://www.beaconequity.com/m – Click on News and Commentary
Join the fastest growing investor community at: http://www.stockhideout.com/
BeaconEquity.com’s Market News is one of the fastest growing small cap blogs in the investment community. Beacon is the authority on research in the small cap sector, and our analysts strive each day to find the stocks that are poised to be the biggest movers before the rest of the market is aware of them.
We encourage investors to subscribe to our FREE newsletter filled with daily trading ideas by visiting:
http://www.beaconequity.com/m
BeaconEquity.com is one of the industry’s largest small cap research providers. Beacon strives to provide a balanced view of many promising small cap companies that would otherwise fall under the radar of the typical Wall Street investor. We provide investors with an excellent first step in their research and due diligence by providing daily trading ideas, and consolidating the publicly available information available on them. For more information on Beacon Research, please visit: http://www.beaconequity.com/m
Source: BeaconEquity.com
Beacon Equity Research
Jeff Bishop, (469)-252-3505
press@beaconequity.com
Press Release Keywords:
stock market, investing, investment ideas, market activity, small caps, micro caps, search engines, technology stocks, blue chips, marketing solutions, beaconequity.com, imclone systems inc.
stock market, investing, investment ideas, market activity, small caps, micro caps, search engines, technology stocks, blue chips, marketing solutions, beaconequity.com, imclone systems inc.